about
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid TumorsSafety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid TumorsSafety of ON 01910.Na in Patients With MyelodysplasiaThree Dosing Schedules of Oral Rigosertib in MDS PatientsMetabolism and Excretion of [14C]-Rigosertib After Infusion to VolunteersPlatinum-based Chemoradiotherapy and Rigosertib in Head and Neck CancerEfficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabinePhase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineOral Rigosertib in Low Risk MDS Patients Refractory to ESAsEfficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeDose Escalation Study of Gemcitabine and ON 01910.Na in Solid TumorsSafety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromePhase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High RiskEfficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High RiskEffect of 2-h Infusion of ON 01910.Na in Ovarian Cancer PatientsStudy of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLPhase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)Oral Rigosertib for Squamous Cell CarcinomaSingle-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaControlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMARigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCCRigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
P4844
Q63832442-5119210B-6F3E-42B8-A958-5C4CABCF377CQ63832696-E3C1CFE2-A36B-46A5-BE5A-43134F7853B6Q63832953-99A14840-0A67-41F5-B93A-A34A48D78240Q64150589-86E59C96-F809-4F59-B635-041DBA0405D3Q64222359-90854727-484A-4765-9FFC-D77BBD82CA5DQ64349345-9ED3B65E-980F-4620-83A7-6A74B3BF1CDFQ64611882-6A5AEC77-9815-430B-9CE4-5461B4FA654BQ64621110-B0198F20-4A94-4ACC-BC34-1F155018C2CFQ64621451-B8D8B8E6-AF07-4C7D-BB91-8458E063FBF2Q64623031-C14B8A14-8191-4BDF-9A1B-50B6CE8A37F7Q64643949-F7D9E79B-CF61-472B-98B5-63A107E3ACA6Q64655632-155B0E67-2E3C-4682-8D14-A2387E82C151Q64657582-14DBA1D6-573D-4443-9A3E-B5AF7BF83F7AQ64662017-C31F79DD-6BD1-415A-A1AE-D5378C027D2EQ64675716-A9FDD698-7A24-4155-AF62-7FEBB694B551Q64679224-8859CB68-75F7-4739-A1D7-76F9EBE15EBDQ64679517-6A34CB88-9D28-4C18-9BB5-6947C9F10D69Q64679569-3D4FD3E0-6B52-4C87-A893-A20125B2E7F3Q66344732-1B23981B-4A1A-48CC-AA91-F4F10ECD5C9DQ66546799-92A926AA-50D7-442A-AA86-8B44C00CE1DEQ67126003-CB17210F-2994-4060-AADF-0A25DDD16D92Q76981808-F66049FB-30C7-4131-ACD6-8766862A5654Q86302200-C2CD16DD-C67F-482B-80F3-4DA250095D93
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Rigosertib
@de
rigosertib
@en
リゴサチブ
@ja
type
label
Rigosertib
@de
rigosertib
@en
リゴサチブ
@ja
altLabel
Estybon® (proposed trade name)
@en
ON-01910
@en
ON01910.Na
@en
Rigosertib
@en
prefLabel
Rigosertib
@de
rigosertib
@en
リゴサチブ
@ja
P486
P592
P6366
P661
P662
P2017
COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
P2067
P2275
rigosertib
@en
P231
592542-59-1
P233
COC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
P234
1S/C21H25NO8S/c1-27-15-10-19(2 ...... ,12-13H2,1-4H3,(H,23,24)/b8-7+
P235
OWBFCJROIKNMGD-BQYQJAHWSA-N
P274
C₂₁H₂₅NO₈S
P3117
DTXSID30207984
P486
P592
CHEMBL1241855
P6366
2780646339
P652
67DOW7F9GL